Vanda wins FDA nod for motion sickness treatment
Share
Vanda Pharmaceuticals (NASDAQ:VNDA) has secured U.S. Food and Drug Administration approval for NEREUS™ (tradipitant), ending a four-decade drought in new pharmacological treatments for motion sickness.
